3.44Open1.25Pre Close6 Volume22 Open Interest15.00Strike Price873.00Turnover352.72%IV58.85%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry1.60Extrinsic Value100Contract SizeAmericanOptions Type0.4144Delta0.0566Gamma7.08Leverage Ratio-0.1074Theta0.0010Rho2.94Eff Leverage0.0076Vega
Alto Neuroscience Stock Discussion
Core business and technology:
Personalized Medication: Alto Neuroscience’s goa...
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet